| dc.contributor.author | Takako Inoue | |
| dc.contributor.author | Shintaro Yagi | |
| dc.contributor.author | Yasuhito Tanaka | |
| dc.contributor.other | Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya 467-8602, Japan | |
| dc.contributor.other | Research and Development Department, Advanced Life Science Institute, Inc., Hachioji 192-0031, Japan | |
| dc.contributor.other | Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan | |
| dc.date.accessioned | 2024-06-26T15:35:13Z | |
| dc.date.accessioned | 2025-10-08T08:24:07Z | |
| dc.date.available | 2025-10-08T08:24:07Z | |
| dc.date.issued | 01-05-2024 | |
| dc.identifier.uri | http://digilib.fisipol.ugm.ac.id/repo/handle/15717717/35755 | |
| dc.description.abstract | Hepatitis B core-related antigen (HBcrAg) reflects the activity of intrahepatic covalently closed circular DNA. HBcrAg can be detected even in chronic hepatitis B patients in whom serum HBV DNA or hepatitis B surface antigen is undetectable. The HBcrAg measurement system was developed based on two concepts. One is a fully-automated and highly-sensitive HBcrAg assay (iTACT-HBcrAg) and the other is a point-of-care testing (POCT) that can be used in in resource-limited areas. iTACT-HBcrAg is an alternative to HBV DNA for monitoring HBV reactivation and predicting the development of hepatocellular carcinoma. This validated biomarker is available in routine clinical practice in Japan. Currently, international guidelines for the prevention of mother-to-child transmission recommend anti-HBV prophylaxis for pregnant women with high viral loads. However, over 95% of HBV-infected individuals live in countries where HBV DNA quantification is widely unavailable. Given this situation, a rapid and simple HBcrAg assay for POCT would be highly effective. Long-term anti-HBV therapy may have potential side effects and appropriate treatment should be provided to eligible patients. Therefore, a simple method of determining the indication for anti-HBV treatment would be ideal. This review provides up-to-date information regarding the clinical value of HBcrAg in HBV management, based on iTACT-HBcrAg or POCT. | |
| dc.language.iso | EN | |
| dc.publisher | MDPI AG | |
| dc.subject.lcc | Microbiology | |
| dc.title | Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening | |
| dc.type | Article | |
| dc.description.keywords | hepatitis B core-related antigen (HBcrAg) | |
| dc.description.keywords | covalently closed circular DNA (cccDNA) | |
| dc.description.keywords | HBV reactivation | |
| dc.description.keywords | point-of-care testing (POCT) | |
| dc.description.keywords | mother-to-child transmission (MTCT) | |
| dc.description.doi | 10.3390/v16060848 | |
| dc.title.journal | Viruses | |
| dc.identifier.e-issn | 1999-4915 | |
| dc.identifier.oai | 3c7fd511f3cc47a29af7cf75002202e9 | |
| dc.journal.info | Volume 16, Issue 6 | |
